(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2019 (12.09.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/173420 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/30* (2006.01)
C07K 16/28 (2006.01) *C07K 16/32* (2006.01)

(21) International Application Number:
PCT/US2019/020872

(22) International Filing Date:
06 March 2019 (06.03.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/640,288 08 March 2018 (08.03.2018) US
62/714,254 03 August 2018 (03.08.2018) US

(71) Applicant: **PHANES THERAPEUTICS, INC.** [US/US]; 9215 Brown Deer Road, Suite B, San Diego, CA 92121 (US).

(72) Inventors: **WANG, Minghan**; 3672 Covington Ln, Doylestwon, PA 18902 (US). **ZOU, Hui**; 3443 Binkley Ave., Dallas, TX 75205 (US). **JIA, Haiqun**; 8028 Camino Jonata, San Diego, CA 92122 (US).

(74) Agent: **BARANIAK, Andrew P.** et al.; Panitch Schwarze Belisario & Nadel LLP, Two Commerce Square, 2001 Marked Street, Suite 2800, Philadelphia, PA 19103 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF



FIG. 1A

(57) Abstract: Anti-CLDN18.2 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer and/or an inflammatory disease.

WO 2019/173420 A1